Impax threatened to launch at risk
Drugmaker Impax said it could have marketed a generic version of Opana ER – even with the possibility of a patent infringement suit – before ultimately agreeing to be paid $112 million in 2010 to end ongoing litigation.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10